GIC backs Esco Lifesciences in oversubscribed US$200m Series A round
Add BT as a preferred source
SINGAPORE-BASED Esco Lifesciences, which supplies life sciences tools for the healthcare industry, has raised US$200 million in an oversubscribed Series A round, as it seeks to expedite expansion in China, and hunt down acquisitions worldwide.
The company is preparing to go public in Hong Kong in the coming months, according to a person familiar with the matter, after its latest round valued it at over US$800 million following the fundraising.
The fundraising, also billed as its crossover round, was led by US-based healthcare investment firm Vivo Capital and Denmark-based life science investor Novo Holdings, the venture arm of Novo Nordisk Foundation.
TRENDING NOW
On the board but frozen out: The Taib family feud tearing Sarawak construction giant apart
Is it time to scrap COE categories for cars?
Thai and Vietnamese farmers may stop planting rice because of the Iran war. Here’s why
Former manager with DBS Bank admits cheating 7 victims, including his uncle, of over S$1 million
